Showing all 8 results
Capecitabine Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Cytotoxic Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
Active Ingredient Strength Primary Clinical Function Capecitabine USP/Ph.Eur. 150 mg The Precision Titration Anchor: Utilized for accurate dose adjustments based on Body Surface Area (BSA). Capecitabine USP/Ph.Eur. 500 mg The Oncology Macrodose: The primary therapeutic unit for standard cycles in Colorectal and Breast cancer. Excipients Proprietary Matrix High-Containment Coating: Engineered with an impenetrable film-coat to prevent the release of cytotoxic dust during handling by healthcare professionals. Cefixime & Potassium Clavulanate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Moisture-Protected Tablet, packed exclusively in high-barrier Alu-Alu blister strips to ensure the stability of the highly sensitive Clavulanate payload.
Active Ingredient Strength Primary Clinical Function Cefixime (as Trihydrate) USP/Ph.Eur. 200 mg The 3rd-Gen Payload: Broad-spectrum bactericidal activity targeting resistant Gram-negative bacilli and Enteric pathogens. Potassium Clavulanate Diluted BP/USP 125 mg The Beta-Lactamase Shield: Irreversibly inhibits the enzymes that cause antibiotic resistance. Excipients Proprietary Matrix Moisture-Scavenging Formulation: Engineered specifically utilizing Low-Humidity Processing (RH < 20%). Clavulanic acid is extremely hygroscopic; our tablets use special desiccant-compatible excipients to prevent degradation. Cefixime and Clavulanic Acid Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Moisture-Protected Tablet, packed exclusively in high-barrier Alu-Alu blister strips to ensure the stability of the highly sensitive Clavulanate payload.
Active Ingredient Strength Primary Clinical Function Cefixime (as Trihydrate) USP/Ph.Eur. 200 mg The 3rd-Gen Payload: Broad-spectrum bactericidal activity targeting resistant Gram-negative bacilli and Enteric pathogens. Potassium Clavulanate Diluted BP/USP 125 mg The Beta-Lactamase Shield: Irreversibly inhibits the enzymes that cause antibiotic resistance. Excipients Proprietary Matrix Moisture-Scavenging Formulation: Engineered specifically utilizing Low-Humidity Processing (RH < 20%). Clavulanic acid is extremely hygroscopic; our tablets use special desiccant-compatible excipients to prevent degradation. Cefpodoxime & Clavulanic acid Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Moisture-Protected Tablet, packed exclusively in high-barrier Alu-Alu blister strips to ensure the stability of the highly sensitive Clavulanate payload.
Active Ingredient Strength Primary Clinical Function Cefpodoxime Proxetil USP/Ph.Eur. 200 mg The 3rd-Gen Payload: Broad-spectrum bactericidal activity targeting resistant Gram-negative and Gram-positive pathogens. Potassium Clavulanate Diluted BP/USP 125 mg The Beta-Lactamase Shield: Irreversibly inhibits the enzymes that cause antibiotic resistance. Excipients Proprietary Matrix Moisture-Scavenging Formulation: Engineered specifically utilizing Low-Humidity Processing (RH < 20%). Clavulanic acid is extremely hygroscopic; our tablets use special desiccant-compatible excipients to prevent degradation. Cefpodoxime-Potassium-Clavulanate-Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Moisture-Protected Tablet, packed exclusively in high-barrier Alu-Alu blister strips to ensure the stability of the highly sensitive Clavulanate payload.
Active Ingredient Strength Primary Clinical Function Cefpodoxime Proxetil USP/Ph.Eur. 200 mg The 3rd-Gen Payload: Broad-spectrum bactericidal activity targeting resistant Gram-negative and Gram-positive pathogens. Potassium Clavulanate Diluted BP/USP 125 mg The Beta-Lactamase Shield: Irreversibly inhibits the enzymes that cause antibiotic resistance. Excipients Proprietary Matrix Moisture-Scavenging Formulation: Engineered specifically utilizing Low-Humidity Processing (RH < 20%). Clavulanic acid is extremely hygroscopic; our tablets use special desiccant-compatible excipients to prevent degradation. Cefuroxime Axetil Tablets
FreeProduct Composition & StrengthWe supply this product as a Precision-Blended, Amorphous Solid Dispersion Tablet, packed exclusively in secure, moisture-resistant Alu-Alu blister strips.
Active Ingredient Strength Primary Clinical Function Cefuroxime Axetil USP/Ph.Eur. 250 mg The Pediatric & ENT Anchor: Utilized for Acute Otitis Media, Pharyngitis, and uncomplicated UTIs. Cefuroxime Axetil USP/Ph.Eur. 500 mg The Respiratory Macrodose: Utilized for Community-Acquired Pneumonia, Bronchitis, and early-stage Lyme Disease. Excipients Proprietary Matrix Amorphous Solid Dispersion Technology: Engineered to maintain the API in its highly-soluble amorphous state for maximum clinical cure rates. Cefuroxime Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Amorphous Solid Dispersion Tablet, packed exclusively in secure, moisture-resistant Alu-Alu blister strips to ensure the stability of the hygroscopic prodrug.
Active Ingredient Strength Primary Clinical Function Cefuroxime Axetil USP/Ph.Eur.
(Equivalent to Cefuroxime)250 mg The Pediatric & ENT Anchor: The definitive unit utilized for the treatment of Acute Otitis Media, Pharyngitis, and uncomplicated Urinary Tract Infections. Cefuroxime Axetil USP/Ph.Eur. 500 mg The Respiratory Macrodose: The high-efficacy therapeutic payload required for the management of Community-Acquired Pneumonia, Bronchitis, and early-stage Lyme Disease. Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Sodium Lauryl Sulfate / Colloidal Silicon Dioxide / Premium Polymeric Film Diluent / Superdisintegrant / Solubilizer / Glidant / Film-Coating (Engineered specifically utilizing Amorphous Solid Dispersion Technology. Because crystalline Cefuroxime Axetil has near-zero bioavailability, our tablets are engineered to maintain the API in its highly-soluble amorphous state for maximum clinical cure rates). *Pack Sizes: 1×6, 1×10, or 10×10 Alu-Alu Blisters (Optimized specifically for strict 5-to-10 day acute curative regimens).
Cinnarizine & Dimenhydrinate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Immediate-Release Tablet, packed exclusively in secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the active antihistamine salts.
Active Ingredient Strength Primary Clinical Function Cinnarizine BP/USP 20 mg The Peripheral Stabilizer: Stops the influx of calcium into the inner ear hair cells to dampen the physical sensation of vertigo. Dimenhydrinate BP/USP 40 mg The Central Antiemetic: Blocks H1 and muscarinic receptors in the brain to prevent nausea and motion-induced vomiting. Excipients Microcrystalline Cellulose / Maize Starch / Talc / Magnesium Stearate / Croscarmellose Sodium Diluent / Binder / Glidant / Superdisintegrant (Engineered specifically utilizing High-Shear Dry Blending to ensure 100% uniformity of the active APIs, providing a rapid disintegration profile that delivers relief within 30 minutes of ingestion). *Pack Sizes: 10×10 Blisters (Optimized specifically for short-course acute vertigo regimens).
